Therapy
Rituximab
Chimeric IgG1 (human Fc + murine variable region) anti-CD20 mAb: ADCC (FcγRIIIa on NK cells), CDC (C1q → MAC), and direct apoptosis signalling.
Also called: RTX, MabThera, Rituxan, anti-CD20
In short
- 1What it is: a therapy in therapies and applications.
- 2How it connects: acts on 4 and is affected by 1 concepts — mostly 1 receptor, 1 pathway, 2 trial.
- 3Where it sits: therapy, trial on the 15-step immune chain.
What it does
RAVE trial (ANCA vasculitis): rituximab = standard induction; BSRBR: serious infection monitoring; secondary antibody deficiency: IgG monitoring 6-monthly with repeat dosing; biosimilars available (rituximab-abbs, -pvvr); IV infusion (slow first dose, infusion reactions); NOT equivalent to ocrelizumab for MS (ocrelizumab humanised → less immunogenic, PPMS approved)
Its connections at a glance
Each dot is a concept directly linked to Rituximab. Colours show the kind of concept.
Sources & evidenceloading…
Loading reviewed sources…
Graph ID I011 · concept status: established. Select any connection above to inspect evidence for that specific link.